Protective effect of clove oil and eugenol microemulsions on fatty liver and dyslipidemia as components of metabolic syndrome

Journal of Medicinal Food

Volumn 17, Issue 7, 2014, Pages 764-771

  Al Okbi, Sahar Y ^a   Mohamed, Doha A ^a   Hamed, Thanaa E ^a   Edris, Amr E ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

clove oil; eugenol; fatty liver; microemulsions; protective effect

Indexed keywords

CHOLESTEROL; CLOVE OIL; EUGENOL; FRUCTOSE; MALONALDEHYDE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; EMULSION; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DYSLIPIDEMIA; FATTY LIVER; LIPID LIVER LEVEL; LIVER DYSFUNCTION; LIVER FUNCTION; LIVER PROTECTION; MALE; METABOLIC SYNDROME X; MICROEMULSION; NONHUMAN; OXIDATIVE STRESS; PARTICLE SIZE; PRIORITY JOURNAL; RAT; ANIMAL; BLOOD; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DYSLIPIDEMIAS; EMULSION; LIVER; LIVER DISEASES; METABOLISM; ORAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; CHOLESTEROL; CLOVE OIL; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSLIPIDEMIAS; EMULSIONS; EUGENOL; FATTY LIVER; LIVER; LIVER DISEASES; MALE; MALONDIALDEHYDE; METABOLIC SYNDROME X; NANOPARTICLES; PARTICLE SIZE; RATS; RATS, SPRAGUE-DAWLEY; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84904284572     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2013.0033     Document Type: Article

References (53)

1. Moon E, Kim Y, Cha D: Synergistic effect between clove oil and its major compounds and antibiotics against oral bacteria. Arch Oral Biol 2011; 56(9): 907-916.
2. Edris A: Pharmaceutical and therapeutic potentials of essential oils and their individual volatile constituents: a review. Phytother Res 2007; 21: 308-323. (Pubitemid 46603595)
3. Uju D, Obioma P: Anticariogenic potentials of clove, tobacco and bitter kola. Asian Pac J Trop Med 2011; 4(10): 814-818.
4. Fei U, Yi-cheng D, Xing-qian E, Yu-ting D: Antibacterial effect of cinnamon oil combined with thyme or clove oil. Agric Sci China 2011; 10(9): 1482-1487.
5. Guan W, Shufen L, Ruixiang Y, Tang S, Quan, C: Comparison of essential oils of clove buds extracted with supercritical carbon dioxide and three other traditional extraction methods. Food Chem 2007; 101: 1558-1564. (Pubitemid 44466243)
6. Edris A: Identification and absolute quantification of the major water-soluble aroma components isolated from the hydrosols of some aromatic plants. J Essn. Oil Bearing Plants 2009; 12(2): 155-161.
7. Nagababu E, Lakshmaiah N: Inhibitory effect of eugenol on non-enzymatic lipid peroxidation in rat liver mitochondria. Biochem Pharmacol 1992; 43(11): 2393-2400.
8. Nishijima H, Uchida R, Kimiko K, Kawakami N, Ohkuba T, Kitamura K: Mechanisms mediating the vasorelaxing action of eugenol, pungent oil, on rabbit arterial tissues. Jpn J Pharmacol 1999; 79(3): 327-334. (Pubitemid 29168143)
9. Yogalakshmi B, Viswanathan P, Anuradha C: Investigation of antioxidant, anti-inflammatory and DNA-protective properties of eugenol in thioacetamide-induced liver injury in rats. Toxicol 2010; 268: 204-212.
10. Nagababu E, Rifkind M, Boindala S, Nakka L: Assessment of antioxidant activity of eugenol in vitro and in vivo. Methods Mol Biol 2010; 610: 165-180.
11. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani, S: Prevalence of and risk factors for non-alcoholic fatty liver disease: the Dionysos nutrition and liver study. He-patol 2005; 42: 44-52. (Pubitemid 40911310)
12. Boccato S, Pistis R, Noventa F, Guido M, Benvegnù L, Alberti A: Fibrosis progression in initially mild chronic hepatitis C. J Viral Hepat 2006; 13: 297-302.
13. Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L. Col-loredo G, Adinolfi E, Asselah T, Jonsson R, Smedile A, Terrault N, Pazienza V, De Lalla F, Giostra E, Sonzogni A, Ruggiero G, Marcellin P, Powell E, George J, Negro F: The relationship between hepatic steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastro-enterol 2006; 130: 1636-1642.
14. Sass A, Chang, P, Chopra B: Nonalcoholic fatty liver disease: a clinical review. Dig Dis Sci 2005; 50:171-180. (Pubitemid 40379159)
15. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Car-ucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Riz-zetto M: Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterol 2002; 123: 134-140. (Pubitemid 34747534)
16. Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villa-nova N, David E, Rizzetto M, Marchesini G: A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005; 100 (5): 1082-1090. (Pubitemid 40769045)
17. Kern A, Ranganathan S, Li C, Wood L., Ranganathan, G: Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am. J. Physiol. Endocrinol Metab 2001; 280(5): E745-E751.
18. Mehta K, Van Thiel H, Shah N, Mobarhan S: Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants. Nutr Rev 2002; 60(9): 289-293. (Pubitemid 35025794)
19. Wang M, Thanou M: Targeting nanoparticles to cancer. Pharmacol Res 2010; 62: 90-99.
20. Edris A: Formulation and shelf life stability of water-borne lecithin nanoparticles for potential application in dietary supplements field. J Dietary Suppl 2012; 9(3): 211-222.
21. Hood E, Simone E, Wattamwar P, Dziubla T, Muzykantov V: Nanocarriers for vascular delivery of antioxidants. Nanomedicine (Lond) 2011; 6(7): 1257-1272.
22. Huang Q, Yu H, Ru Q: Bioavailability and delivery of nu-traceuticals using nanotechnology. J Food Sci 2010; 75(1): R50-R57.
23. Edris A, Malone C: Preferential solubilization behaviors and stability of some phenolic-bearing essential oils formulated in different microemulsion systems. Int J Cosmetic Sci 2012; 34: 441-450.
24. Edris A, Malone C: Alcohol-free delivery system carrying thyme essential oil nanoparticles formulated via microemulsion technique. Advanc Sci Eng Med 2011; 13: 219-225.
25. Watson D: A simple method for the determination of serum cholesterol. Clin Chem Acta 1960; 5: 637-642.
26. Burstein M, Scholnick H, Morfin R: Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. Scand J Clin Lab Inves. 1980; 40: 583-595.
27. Gerard T, Gerald L: Process and reagents for the selective separation of low density lipoprotein (LDL) and for the quantification of their components. Eur Path (Appl) 1981; EP 76: 211-223.
28. Megraw R, Dunn D, Biggs H: Manual and continuous flow colorimetry of triglycerols by a fully enzymatic method. Clin Chem 1979; 25: 273-284.
29. Satoh K: Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. Clinica Chimica Acta 1978; 20: 37-43. (Pubitemid 9055456)
30. Stepaniak A, Gould E, Sun D, Swanborg H: A comparative study of experimental autoimmune encephalomyelitis in Lewis and DA rats. J Immunol 1995; 155: 2762-2769.
31. Reitman S, Frankel S: Colorimetric methods for aspartate and alanine aminotransferase. Am J Clin Path 1957; 28: 55-60.
32. Gambino R: In: Standard Methods of Clinical Chemistry/American Association of Clinical Chemists, Vol. 5 (Meites S, ed.) Academic Press, 1965, pp. 55-64.
33. Folch J, Lees M, Sloane Stanley H: A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957; 226: 497-509.
34. Cequier-Sánchez E, Rodŕiguez C, Ravelo G, Zárate R: Di-chloromethane as a solvent for lipid extraction and assessment of lipid classes and fatty acids from samples of different natures. J Agric Food Chem 2008; 56(12): 4297-303. (Pubitemid 352002670)
35. Joint FAO/WHO expert committee on food additives. Tox-icological evaluation of some food additives including anti-caking, antimicrobial, antioxidant, emulsifiers and thickening agents. WHO Food Additives series 1974, No. 5.
36. Hamed S, Sadek Z, Edris A: Antioxidant and antimicrobial activities of clove bud essential oil and eugenol nanoparticles in alcohol-free microemulsion. J Oleo Sci 2012; 61(11): 641-648.
37. Helenius A, McCaslin R, Fries E, Tanford C: Properties of detergents. Methods Enzymol 1979; 56: 734-749.
38. Joint FAO/WHO expert committee on food additives. Safety evaluation of certain food additives. WHO Food Additives series 2006, No. 56.
39. Nangle R, Gibson M, Cotter A, Cameron E: Effects of eugenol on nerve and vascular dysfunction in streptozotocin-diabetic rats. Planta Med 2006; 72(6): 494-500.
40. Nagababu E, Sesikeran B, Lakshmaiah N: The protective effects of eugenol on carbon tetrachloride-induced hepatotoxicity in rats. Free Radic Res 1995; 23(6): 617-27.
41. Morsy A, Fouad, A: Mechanisms of gastroprotective effect of eugenol in indomethacin-induced ulcer in rats. Phytother Res 2008; 22(10): 1361-1366.
42. Dekker J, Su Q, Baker C, Rutledge C, Adeli K: Fructose: a highly lipogenic nutrient implicated in insulin resistance, hepatic stea-tosis, and the metabolic syndrome. Am J Physiol Endocrinol Metab 2010; 299(5): E685-E694.
43. Zawadzka-Bartczak E, Kopka L, Gancarz A: Antioxidative enzyme profiles in fighter pilots. Aviat Space Environ Med 2003; 74(6 Pt 1): 654-658. (Pubitemid 36637509)
44. Lê A, Bortolotti M: Role of dietary carbohydrates and macro-nutrients in the pathogenesis of nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care 2008; 11(4): 477-482.
45. Choi C, Savage B, Kulkarni A, Yu X, Liu X, Morino K, Kim S, Distefano A, Samuel T, Neschen S, Zhang D, Wang A, Zhang M, Kahn M, Cline W, Pandey K, Geisler G, Bhanot S, Monia P, Shulman I: Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance. J Biol Chem 2007; 282(31): 22678-22688. (Pubitemid 47267336)
46. Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C: Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med 2008; 14: 72-81.
47. Edmison J, Mccullough, J: Pathogenesis of non-alcoholic stea-tohepatitis: human data. Clin Liver Dis 2007; 11(1): 75-104. (Pubitemid 46829977)
48. Parola M, Robino, G: Oxidative stress-related molecules and liver fibrosis. J Hepatol 2001; 35: 297-306. (Pubitemid 32803489)
49. Vozarova B, Stefan N, Lindsay S, Saremi A, Pratley E, Bogardus C, Tataranni A: High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002; 51: 1889-1895. (Pubitemid 34564303)
50. Choi K, Cho S, Hwang S, Kim W, Lim H, Lee C, Kim C, Kim K, Kim S: Methyl eugenol reduces cerebral ischemic injury by suppression of oxidative injury and inflammation. Free Radic Res 2010; 44(8): 925-935.
51. Fouad A, Yacoubi T: Mechanisms underlying the protective effect of eugenol in rats with acute doxorubicin cardiotoxicity. Arch Pharm Res 2011; 34(5): 821-828.
52. Michiels J, Missotten J, Dierick N, Fremaut D, Maene P, De Smet S: In vitro degradation and in vivo passage kinetics of carvacrol, thymol, eugenol and trans-cinnamaldehyde along the gastrointestinal tract of piglets. J Sci Food Agric 2008; 88(13): 2371-2381.
53. Zhao X, Chen D, Gao P, Luo Y, Li K: Synthesis, properties and microemulsion formulation of ibuprofen eugenol ester. Pharmazie 2005; 60 (12): 883-887. (Pubitemid 41820751)